Lymphocyte PKCε Assay for Alzheimer's Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Alzheimer's disease are limited by their focus on brain-related pathophysiology, and there is a need for more accurate and systemic approaches that can detect the disease through non-invasive means, such as skin cell assays, which may not fully capture the complexity of the disease's systemic expression.
Innovation Solution
The development of lymphocyte-based methods that involve culturing lymphocytes under conditions to preserve viability and measuring the level of PKCε, comparing it with controls, and using amylospheroid concentrations to differentiate between Alzheimer's disease and other conditions, providing a systemic and non-invasive diagnostic and predictive tool.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If skin cell-based assays are used to diagnose Alzheimer's disease, then non-invasive detection is achieved, but the complexity of the disease's systemic expression cannot be fully captured
Solution Approach 1:
The patent changes the cell type parameter from skin fibroblasts to lymphocytes, which are more representative of the immune system's systemic response to Alzheimer's pathology. This parameter change enables both non-invasive detection and capture of systemic disease expression, as lymphocytes can be obtained from blood (non-invasive) and are directly involved in the immune response to amyloid-beta and tau pathology (accurate measurement).
Solution Approach 2:
The patent employs multiple PKC isozyme measurements (PKC-alpha, PKC-beta, PKC-epsilon, PKC-gamma) in combination with amyloid-beta and tau assays on the same lymphocyte sample. This multi-functional approach allows a single blood draw to provide comprehensive diagnostic information about both the immune response and the presence of Alzheimer's pathologies, simultaneously achieving non-invasive detection and accurate disease characterization.
2Measurement precision
If lymphocyte culturing is performed to measure PKCε levels, then systemic disease expression is captured, but the diagnostic process becomes more complex
Solution Approach 1:
The patent performs lymphocyte culturing and PKC isozyme measurements in advance, before final diagnostic interpretation. By preparing the lymphocytes and measuring baseline PKC levels proactively, the system captures systemic disease expression early in the diagnostic workflow, allowing subsequent analysis to focus on interpreting established data rather than performing multiple complex procedures sequentially.
Solution Approach 2:
The patent combines multiple diagnostic measurements (PKC-alpha, PKC-beta, PKC-epsilon, PKC-gamma levels and their ratios, along with amyloid-beta and tau assays) into a single integrated diagnostic framework using lymphocytes. This merging approach consolidates what would otherwise require multiple separate tests into one unified assay system, reducing overall process complexity while maintaining comprehensive disease detection capability.
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3B
AI summary
This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods involve the steps of (a) culturing lymphocytes from the subject under suitable conditions; (b) measuring the amount of PKCε in the cultured lymphocytes; and (c) comparing the measurement of step (b) with a suitable control.